Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Memorial Sloan Kettering Cancer Center physicians describe challenges in diagnosis, patient care, and the potential expansion of telehealth in this continuation of November's coverfeature.

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

Morgans analyst Iain Wilkie said 2024 was "pretty patchy" for the ASX healthcare sector, which underperformed broader markets ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

It's a lost opportunity to promote a healthy gut microbiome, recover from treatment-related microbiota injury, and protect against GVHD," said first author Jenny Paredes, PhD, a staff scientist at ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.